Table of Contents Table of Contents
Previous Page  505 / 812 Next Page
Information
Show Menu
Previous Page 505 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S501

2

El-Menia uneversity, faculty of arts, department of psychology,

El-Menia, Egypt

3

Al-Azhar university, faculty of medicine, department of psychiatry,

Cairo, Egypt

4

Mansoura university, faculty of medicine, department of psychiatry,

Mansoura, Egypt

5

Alexandia university, institute of public health, biostatistics

department, Alexandria, Egypt

6

Ain Shams university, faculty of medicine, department of

psychiatry, Cairo, Egypt

7

Zagazig university, faculty of medicine, psychiatry department,

Zagazig, Egypt

Corresponding author.

Objective

to examine the longitudinal effect of depression on

glycemic control in a sample of patients with type 2 diabetes.

Methods

the patients were recruited fromdiabetes clinic in Saudi

airlines medical center, in Jeddah, the base line study commu-

nity consisted from 172 patients with type 2 diabetes. They were

assessed for depression using BDI II, and diagnostic interview, and

for diabetic control using HbA1c. We created a person-period data

set for each patient to cover 6 months intervals up to 3 years. We

used generalized estimation equation (GEE) for analysis of longi-

tudinal data. HbA1C was the response variable while depression

and time were the main covariates. Variables were included in

GEE models based on clinical importance and preliminary analy-

sis. Other variables included as covariates were gender, education,

duration of diabetes, co-morbidity and LDL. All statistical analysis

used = 0.05 level of significance and were performed using SPSS

software version 21.

Results

Unadjusted HbA1c means were significantly higher in

depressed vs. non-depressed subjects at all time points. The

adjusted HbA1c means in final GEE model were significantly

higher in depressed vs. non-depressed subjects. In all adjusted

models depression was a predictor of glycemic control weather

it was BDI score (estimate = .049,

P

= .002), diagnoses of MDD

(estimate = 2.038,

P

= .000), or other depressive diagnosis (esti-

mate = 1.245,

P

= .000).

Conclusion

This study on clinical sample of type 2 diabetic

patients demonstrates that there is a significant longitudinal

relationship between depression and glycemic control and that

depression is associated with persistently higher HbA1c over time.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1461

EV477

Reliability and validity of Turkish

version of DSM-5 level 2 Depression

Adult Scale

E. AydIn Asik

1 ,

, E

. C¸ öldür

1 , K.

As¸ c¸ ibas¸ i

1 , A. H

erdem

1 , D.

Alc¸ i

1 ,

T. Sarikavak

1

, F.P. C¸ ökmüs¸

1

, S. Öztekin

1

, K. Balikc¸ i

1

,

S. Yüzeren Bas¸ sivri

1

, O. Aydin

2

, F. Akdeniz

1

,

D. Sücüllüo˘glu Dikici

1

, E. Köro˘glu

3

, Ö. Aydemir

1

1

Celal Bayar University Faculty of Medicine, Psychiatry, Manisa,

Turkey

2

Bolu KHB Abant ˙Izzet Baysal University Hospital, Psychiatry, Bolu,

Turkey

3

Boylam Psychiatry Institute, Psychiatry, Ankara, Turkey

Corresponding author.

Objective

This study aims to demonstrate the reliability and

validity of Turkish version of DSM-5 level 2 depression adult Scale

which was developed to measure the severity of depression.

Material-methods

The study group included 51 patients who

met the criteria for major depressive disorder according to DSM-

5. Sixty-five volunteers without any mental or physical disease

were also recruited as a control group. Beck Depression Inventory

(BDI), which is the most widely used self-report scale, was used for

concurrent validity. Internal consistency coefficient and item-total

correlation analysis were performed for reliability. Exploratory fac-

tor analysis was used for validity as BDI was used for concurrent

validity.

Results

Mean age was 40.5

±

11.4 in the patient group and

21.8

±

4.9 years in the control group, respectively. A total of 62.1%

of the sample group (

n

= 72) were female. A total of 59.5% of the

groupwere college graduates, 16.4%were primary school graduates

and 14.7% were high school graduates. Disease duration for major

depressive disorderwas 13.5

±

10.5 years for the patient group. The

internal consistency of the Level 2 Depression Adult was 0.96. Item-

total correlation coefficients were between 0.71–0.90 (

P

< 0.0001).

For the exploratory factor analysis of sample adequacy of DSM-5

Level 2 Depression Adult Scale, Kaiser-Meger-Olkin (KMO) coeffi-

cient and Bartlett coefficient was calculated as 0.91 and 1026, 62

(

P

< 0.0000), respectively. Single-factor solution was obtained with

aneigen value of 6.27, representing 78.3% of the variance. Factor

loadings of the items were between 0.77–0.92. Correlation coef-

ficient of Level 2 Depression Adult Scale with BDI was found as

r

= 0.76 (

P

< 0.0000).

Conclusion

The Turkish version of DSM-5 Level 2 Depression

Adult Scale is reliable and valid.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1462

EV478

Agomelatine vs fluoxetine: Efficacy

and improvement of cognitive

functions in patients with MDD

E. Aydın

1 ,

, M. Gülec¸

2

, E. Oral

2

, A.G. Dalo˘glu

3

1

Atatürk University School of Medicine, Psychiatry, Erzurum, Turkey

2

˙Izmir Katip C¸ elebi University School of Medicine, Psychiatry, ˙Izmir,

Turkey

3

Mersin State Hospital, Psychiatry, Mersin, Turkey

Corresponding author.

Introduction

In major depressive disorder (MDD) neurocogni-

tive functions are impaired. In addition to melatonergic properties

of agomelatine, via 5-HT2C antagonism it increases extracellular

noradrenaline and dopamine in frontal cortex and may improve

the neurocognitive functions of patients with MDD.

Aims and objectives

To investigate the extent of neurocognitive

improvement and efficacy of agomelatine andfluoxetine inpatients

with MDD.

Material and method

Agomelatine 25mg/day (

n

: 24) and fluoxe-

tine 20mg/day (

n

: 24) were administered to drug-naive unipolar,

non-psychotic, non-suicidal MDD patients according to DSM-IV.

Evaluations were performed just before the treatment and at

the sixth week of treatment via administering Hamilton Depres-

sion Rating Scale, Rey Auditory Verbal Learning Test, Controlled

Oral Word Association Test (COWAT), Digit Span Test (DST), Trail

Making Test (TMT-A/B), Stroop Test and Wisconsin Card Sorting

Test.

Results

Both agomelatine and fluoxetine was found to be effica-

cious for the treatment of MDD (

P

< 0.05 for both). Further there

was no difference between the antidepressant efficacy of two

drugs. Both of the drugs improved measured neurocognitive func-

tions (

P

< 0.05), except scores of DST (

P

> 0.05) and only fluoxetine

improved significantly scores of COWAT (

P

< 0.05). Only in terms of

TMT-B therewas significant difference between groups and agome-

latine was superior to fluoxetine (

P

< 0.05).

Conclusion

Agomelatine and fluoxetine were efficacious in treat-

ment of MDD. Furthermore both of the drugs improved cognitive

functions in patients with MDD. Superiority of agomelatine in

improvement of executive functioning (TMT-B) is important and

therefore it could be an appropriate choice for MDD patients who

have pronounced executive disturbances.